Nuvo (AMEX:NUVO)
Historical Stock Chart
From Jun 2019 to Jun 2024
Nuvelo to be Featured at the Third Annual JMP Securities Research Conference
SUNNYVALE, Calif., March 4 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq:
NUVO; interim ticker symbol: NUVOD) today announced that Ted W. Love, M.D.,
president and CEO, will be presenting at the Third Annual JMP Securities
Research Conference in San Francisco, California, on Tuesday, March 9, 2004 at
2:50 p.m. Pacific Time.
Dr. Love will provide a brief corporate overview and discuss the company's
recently expanded pipeline and near-term milestones. A live audio webcast of the
presentation will be available online via the Investor Relations portion of
Nuvelo's Web site at http://www.nuvelo.com/ or at
http://w.on24.com/r.htm?e=5221&s=1&k=A588DCA3E7E830DE49B14E0B4B4A2811 .
About Nuvelo
Nuvelo, Inc. is engaged in the discovery, development and commercialization of
life improving therapeutics for the treatment of human disease. Nuvelo's lead
product candidate, alfimeprase, is partnered with Amgen and is currently in two
Phase 2 trials in two indications, peripheral arterial occlusion and catheter
occlusion. Additional programs include cardiovascular product candidates ARC183
and rNAPc2 and drug discovery focused on antibody targets and secreted
proteins.
Information about Nuvelo is available at our new Web site at
http://www.nuvelo.com/ or by phoning 408-215-4000.
DATASOURCE: Nuvelo, Inc.
CONTACT: Pete Garcia, Sr. VP and Chief Financial Officer,
+1-408-215-4574, or , or Nicole Estrin, Manager of Corporate
Communications & IR, +1-408-215-4572, or , both of Nuvelo,
Inc.
Web site: http://www.nuvelo.com/